RT Journal Article
SR Electronic
T1 Trends of drug use with suggested shortages and their alternatives across 41 real world data sources and 18 countries in Europe and North America
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.08.28.24312695
DO 10.1101/2024.08.28.24312695
A1 Pineda-Moncusí, Marta
A1 Rekkas, Alexandros
A1 Pérez, Álvaro Martínez
A1 Leis, Angela
A1 Gomez, Carlos Lopez
A1 Bruninx, Erwin
A1 Maljković, Filip
A1 Rodeiro, Jordi
A1 Franz, Michael
A1 Mayer, Miguel-Angel
A1 Eleangovan, Neva
A1 Natsiavas, Pantelis
A1 Şen, Selçuk
A1 Cooper, Steven
A1 Reisberg, Sulev
A1 Manlik, Katrin
A1 Sánchez-Sáez, Francisco
A1 del Pino, Beatriz
A1 Uribe, Albert Prats
A1 Üresin, Ali Yağız
A1 Bastić, Ana Danilović
A1 Rodrigues, Ana Maria
A1 Palomar-Cros, Anna
A1 Verbiest, Annelies
A1 Erdoğan, Barış
A1 Keuthage, Carina Dinkel-
A1 Torre, Carmen Olga
A1 de Beukelaar, Caroline
A1 Eteve-Pitsaer, Caroline
A1 Gonçalves, Cátia F.
A1 de Palma, Costantino
A1 Gavina, Cristina
A1 Dedman, Daniel
A1 Price, David Brendan
A1 Balan, Denisa Gabriela
A1 Enders, Dirk
A1 Henke, Elisa
A1 Scheurwegs, Elyne
A1 Callewaert, Emma
A1 Martínez, Encarnación Pérez
A1 Tan, Eng Hooi
A1 Fey, Eric
A1 Prasser, Fabian
A1 Staelens, Frank
A1 Nyberg, Fredrik
A1 Candore, Gianmario
A1 Mestdach, Gianny
A1 Shachaf, Hadas
A1 Li, Huiqi
A1 Reinecke, Ines
A1 López-Sánchez, Irene
A1 de la Cruz Bertolo, Javier
A1 Evers, Jelle
A1 Firmino-Machado, João
A1 Wastesson, Jonas
A1 Bermúdez, Juan Luis Cruz
A1 Ramírez-Anguita, Juan Manuel
A1 Porkka, Kimmo
A1 Johnell, Kristina
A1 Cool, Lieselot
A1 Kiss, Loretta Zsuzsa
A1 Moscetti, Luca
A1 Merkelbach, Manon
A1 Canelas-Pais, Mariana
A1 Dominici, Massimo
A1 Szilcz, Máté
A1 Puntoni, Matteo
A1 Mosseveld, Mees
A1 Tadrous, Mina
A1 Bové, Mona
A1 Rappoport, Nadav
A1 Barrio, Noelia García
A1 Ettala, Otto
A1 Baili, Paolo
A1 Pulido, Pau Pericàs
A1 Mayo, Paula Rubio
A1 Prinsen, Peter
A1 Norris, Raeleesha
A1 Claire, Ravinder
A1 Lillini, Roberto
A1 Lazzarelli, Silvia
A1 Duarte-Salles, Talita
A1 Taveira-Gomes, Tiago
A1 Jansen, Tim
A1 Keilholz, Ulrich
A1 Li, Xintong
A1 Prieto-Alhambra, Daniel
A1 Rijnbeek, Peter R.
A1 Burkard, Theresa
YR 2024
UL http://medrxiv.org/content/early/2024/08/29/2024.08.28.24312695.abstract
AB Importance Drug production not meeting the demand leaves affected patients in a vulnerable position.Objective To describe incidence and prevalence of medicines with suggested shortages in at least one European countryDesign We performed a descriptive cohort study between 2010 in a network of databases which have mapped their data to the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM).Setting Setting included primary care, secondary care, and various disease registries whose previously collected data was leveraged.Participants We included all patients with at least 365 days of history on the database.Exposures We investigated all medicines with a suggested shortage in at least one European country for more than 365 days (n=18). Furthermore, we assessed their alternatives as well (n=39).Main outcomes and measures We estimated annual incidence rates and period prevalence of all medicines with suggested shortages and their alternatives. A drop in incidence or prevalence of more than 33% after the shortage announce by the European Medicines Agency was considered confirmation of a shortage.Results Among 41 databases from Europe and the United States, we observed shortages according to incidence for 12 drugs and shortages according to prevalence for 4 drugs. The drugs varenicline, cetrorelix, and amoxicillin plus clavulanate were in shortage in the most countries.Conclusion and relevance We compiled and analysed data of annual incidence and prevalence of 57 medicines among 41 databases in Europe and the United States. We detected shortages of several drugs and suggest monitoring and stewardship for drug availability.Competing Interest StatementAMR declares consulting and/or speaking from Abbvie, Amgen; Research grant from Novartis, Pfizer, Amgen. APU has received consultancy fees from Synapse Partners unrelated to the work. CDK is a full-time employee of Bayer AG. CGdeclares consulting and/or speaking from AstraZeneca, Bayer, BIAL, Boehringer-Ingelheim, Daiichi Sankyo, Lilly, MSD, Novartis and Novo Nordisk. CT holds shares and is an employee at Roche Pharmaceuticals. DBP has advisory board membership with AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis, Viatris, Teva Pharmaceuticals; consultancy agreements with AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis, Viatris, Teva Pharmaceuticals; grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute Pte Ltd) from AstraZeneca, Chiesi, Viatris, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, and UK National Health Service; payment for lectures/speaking engagements from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Inside Practice, GlaxoSmithKline, Medscape, Viatris, Novartis, Regeneron Pharmaceuticals and Sanofi Genzyme, Teva Pharmaceuticals; payment for travel/accommodation/meeting expenses from AstraZeneca, Boehringer Ingelheim, Novartis, Medscape, Teva Pharmaceuticals.; owns 74 of the social enterprise Optimum Patient Care Ltd (Australia and UK) and 92.61 of Observational and Pragmatic Research Institute Pte Ltd (Singapore); is peer reviewer for grant committees of the UK Efficacy and Mechanism Evaluation programme, and Health Technology Assessment; and was an expert witness for GlaxoSmithKline. EB owns Pfizer Shares. EHT received consultancy fees from Janssen Pharmaceutica NV, outside the submitted work. FN owns some AstraZeneca shares. GC is a full-time employee of Bayer AG. KM is a full time employee of Bayer AG. MT has received consulting fees from Health Canada and CDA. PR works for a research group that receives/received unconditional research grants from Chiese, GSK, UCB, Amgen, Johnson and Johnson, European Medicines Agency, none of which relate the content of this manuscript. TB declares consultant for IBSA. DPA's research group has received grant/s from Amgen, Chiesi-Taylor, Lilly, Janssen, Novartis, and UCB Biopharma. His research group has received consultancy fees from Astra Zeneca and UCB Biopharma. Amgen, Astellas, Janssen, Synapse Management Partners and UCB Biopharma have funded or supported training programmes organised by DPA's department.Clinical Protocols https://catalogues.ema.europa.eu/node/3843/administrative-details Funding StatementFunding This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806968. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Use of Clinical Practice Research Datalink (CPRD) data for this study was approved via the Research Data Governance (RDG) Process of the UK Medicines and Healthcare Products Regulatory Agency (protocol 23_003389). Ethical approval for Fundacion para la Investigacion del Hospital Universitario La Fe de la Comunidad Valenciana (HULAFE) was obtained from the Comite de etica de la investigacion con medicamentos (number 2024-561-1). Ethical approval for IMIM-Hospital del Mar Barcelona (IMASIS) was obtained by the Parc de Salut Mar Research Ethics Committee CEIm-Parc de Salut Mar (number 2023/11266). Ethical approval number for Hospital District of Helsinki and Uusimaa (HUS) in this study was HUS/325/2023. Ethical approval number for Istanbul University (ITF) was 2302692. Ethical approval number for Netherlands Comprehensive Cancer Organisation (NCR) was K23.338. Ethical approval number for University Medicine Dresden (UM DRESDEN) was SR-EK-181052024. Ethical approval number for Optimum Patient Care Limited (OPCRD) was ADEPT0624. Ethical approval number for Clinical-hospital center Zvezdara (CHCZ) was FWA00024180. Ethical approval number for Fundacio Institut d'Investigacio Sanitaria Illes Balears (PRISIB) was CI-866-24. Ethical approval number for EGAS MONIZ HEALTH ALLIANCE (EMHA ULSRA and EMHA ULSGE) was 4/2023 Ref 19-CE-ICVS/CAC-EMHA. Ethical approval number for FISABIO-HSRU (VID-CONSIGN) was 2023/382. Ethical approval number for University Hospital Antwerp (UZA) was 5957-EDGE 3372-BUN. Ethical approval number for AZ Groeninge (AZGR) was AZGD2024008. Ethical approval number for Viecuri was 2022_088. Ethical approval number for Charite - Universitatsmedizin (CHA CAN) was EA1/04124. Ethical approval number for THIN databases was 2024-06-R. Ethical approval for The Integrated Primary Care Information Project (IPCI) was obtained by the Integrated Primary Care Information review board (registration number 9/2023).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data sources were previously mapped to the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDMv5). Thus, only aggregated data was shared by each of the data partners. Aggregated data is fully available in the shiny app of the study: https://dpa-pde-oxford.shinyapps.io/MegaStudy_webinar_incprev_BG1/. Access to patient level data are specific to each database and must be requested individually to each data source. Code of the study is fully available in GitHub: https://github.com/oxford-pharmacoepi/MegaStudy https://github.com/oxford-pharmacoepi/MegaStudy https://dpa-pde-oxford.shinyapps.io/MegaStudy_webinar_incprev_BG1/